## Adrienne C Lahti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5060341/publications.pdf

Version: 2024-02-01

61945 53190 7,730 128 43 85 citations h-index g-index papers 129 129 129 8530 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia. Neuropsychopharmacology, 1995, 13, 9-19.	2.8	<b>7</b> 53
2	Effects of Ketamine in Normal and Schizophrenic Volunteers. Neuropsychopharmacology, 2001, 25, 455-467.	2.8	576
3	Spatial and Temporal Mapping of De Novo Mutations in Schizophrenia to a Fetal Prefrontal Cortical Network. Cell, 2013, 154, 518-529.	13.5	507
4	Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport, 1995, 6, 869-872.	0.6	423
5	Gamma and Delta Neural Oscillations and Association with Clinical Symptoms under Subanesthetic Ketamine. Neuropsychopharmacology, 2010, 35, 632-640.	2.8	238
6	Probing the human hippocampus using rCBF: Contrasts in schizophrenia. Hippocampus, 2001, 11, 543-550.	0.9	233
7	SLC7All expression is associated with seizures and predicts poor survival in patients with malignant glioma. Science Translational Medicine, 2015, 7, 289ra86.	5.8	207
8	Neurometabolites in schizophrenia and bipolar disorder â€" A systematic review and meta-analysis. Psychiatry Research - Neuroimaging, 2012, 203, 111-125.	0.9	179
9	Increased Hippocampal Glutamate and Volumetric Deficits in Unmedicated Patients With Schizophrenia. JAMA Psychiatry, 2013, 70, 1294.	6.0	179
10	Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder—a systematic review of the magnetic resonance neuroimaging literature. NPJ Schizophrenia, 2017, 3, 15.	2.0	164
11	Ventral Tegmental Area/Midbrain Functional Connectivity and Response to Antipsychotic Medication in Schizophrenia. Neuropsychopharmacology, 2014, 39, 1020-1030.	2.8	145
12	Sequential Regional Cerebral Blood Flow Brain Scans Using PET with H2150 Demonstrate Ketamine Actions in CNS Dynamically. Neuropsychopharmacology, 2001, 25, 165-172.	2.8	137
13	Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biological Psychiatry, 2003, 53, 601-608.	0.7	130
14	Correlations Between rCBF and Symptoms in Two Independent Cohorts of Drug-Free Patients with Schizophrenia. Neuropsychopharmacology, 2006, 31, 221-230.	2.8	122
15	How Low Should You Go? Determining the Optimal Cutoff for Exhaled Carbon Monoxide to Confirm Smoking Abstinence When Using Cotinine as Reference. Nicotine and Tobacco Research, 2014, 16, 1348-1355.	1.4	122
16	Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers. American Journal of Psychiatry, 2006, 163, 488-493.	4.0	117
17	Assessments of Function and Biochemistry of the Anterior Cingulate Cortex in Schizophrenia. Biological Psychiatry, 2010, 68, 625-633.	0.7	115
18	Multimodal neuroimaging based classification of autism spectrum disorder using anatomical, neurochemical, and white matter correlates. Cortex, 2015, 66, 46-59.	1.1	113

#	Article	IF	CITATIONS
19	Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia. Neuropsychopharmacology, 1995, 13, 9-19.	2.8	106
20	Antipsychotic Properties of the Partial Dopamine Agonist (â^')-3-(3-Hydroxyphenyl)-N-n-Propylpiperidine (Preclamol) in Schizophrenia. Biological Psychiatry, 1998, 43, 2-11.	0.7	105
21	Aberrant Hippocampal Connectivity in Unmedicated Patients With Schizophrenia and Effects of Antipsychotic Medication: A Longitudinal Resting State Functional MRI Study. Schizophrenia Bulletin, 2016, 42, 1046-1055.	2.3	104
22	Effects of Noncompetitive NMDA Receptor Blockade on Anterior Cingulate Cerebral Blood Flow in Volunteers with Schizophrenia. Neuropsychopharmacology, 2005, 30, 2275-2282.	2.8	103
23	Abnormal Patterns of Regional Cerebral Blood Flow in Schizophrenia With Primary Negative Symptoms During an Effortful Auditory Recognition Task. American Journal of Psychiatry, 2001, 158, 1797-1808.	4.0	101
24	Change in brain network topology as a function of treatment response in schizophrenia: a longitudinal resting-state fMRI study using graph theory. NPJ Schizophrenia, 2016, 2, 16014.	2.0	100
25	Modulation of Limbic Circuitry Predicts Treatment Response to Antipsychotic Medication: A Functional Imaging Study in Schizophrenia. Neuropsychopharmacology, 2009, 34, 2675-2690.	2.8	94
26	Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone. Neurolmage: Clinical, 2016, 10, 146-158.	1.4	94
27	7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia. Schizophrenia Bulletin, 2019, 45, 180-189.	2.3	94
28	Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia. Neuropsychopharmacology, 2012, 37, 2635-2642.	2.8	83
29	The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. Psychopharmacology, 2005, 183, 265-274.	1.5	80
30	Clozapine but not Haloperidol Re-establishes Normal Task-Activated rCBF Patterns in Schizophrenia within the Anterior Cingulate Cortex. Neuropsychopharmacology, 2004, 29, 171-178.	2.8	76
31	Effective connectivity during episodic memory retrieval in schizophrenia participants before and after antipsychotic medication. Human Brain Mapping, 2015, 36, 1442-1457.	1.9	72
32	Ketamine Effects on Eye Movements. Neuropsychopharmacology, 2000, 23, 645-653.	2.8	71
33	Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging. Schizophrenia Research, 2012, 140, 136-142.	1.1	67
34	Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia. Psychiatry Research - Neuroimaging, 2005, 139, 19-30.	0.9	66
35	Eye Tracking Disorder in Schizophrenia Is Characterized by Specific Ocular Motor Defects and Is Associated with the Deficit Syndrome. Biological Psychiatry, 1997, 42, 781-796.	0.7	58
36	Brain Activation Patterns in Schizophrenic and Comparison Volunteers During a Matched-Performance Auditory Recognition Task. American Journal of Psychiatry, 2000, 157, 1634-1645.	4.0	58

3

#	Article	IF	CITATIONS
37	Dopaminergic synapses in the caudate of subjects with schizophrenia: Relationship to treatment response. Synapse, 2009, 63, 520-530.	0.6	55
38	Hippocampalâ€parietal dysconnectivity and glutamate abnormalities in unmedicated patients with schizophrenia. Hippocampus, 2014, 24, 1524-1532.	0.9	55
39	Memory Deficits in Schizophrenia: A Selective Review of Functional Magnetic Resonance Imaging (fMRI) Studies. Behavioral Sciences (Basel, Switzerland), 2013, 3, 330-347.	1.0	51
40	Effects of Ketamine on Leading Saccades During Smooth-Pursuit Eye Movements May Implicate Cerebellar Dysfunction in Schizophrenia. American Journal of Psychiatry, 2002, 159, 1490-1496.	4.0	50
41	The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders – A systematic review of magnetic resonance spectroscopy studies. Schizophrenia Research, 2022, 249, 74-84.	1.1	50
42	Evaluating Glutamatergic Transmission in Schizophrenia. Annals of the New York Academy of Sciences, 2003, 1003, 113-118.	1.8	48
43	Long-term outcome of patients who receive ketamine during research. Biological Psychiatry, 2001, 49, 869-875.	0.7	47
44	Does pursuit abnormality in schizophrenia represent a deficit in the predictive mechanism?. Psychiatry Research, 1996, 59, 221-237.	1.7	45
45	A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia. Schizophrenia Research, 2016, 170, 341-350.	1.1	45
46	Risperidone Effects on Brain Dynamic Connectivityâ€"A Prospective Resting-State fMRI Study in Schizophrenia. Frontiers in Psychiatry, 2017, 8, 14.	1.3	40
47	Delay discounting and task performance consistency in patients with schizophrenia. Psychiatry Research, 2014, 215, 286-293.	1.7	38
48	Hippocampal glutamate and hippocampus subfield volumes in antipsychotic-naive first episode psychosis subjects and relationships to duration of untreated psychosis. Translational Psychiatry, 2020, 10, 137.	2.4	38
49	A longitudinal neurite and free water imaging study in patients with a schizophrenia spectrum disorder. Neuropsychopharmacology, 2019, 44, 1932-1939.	2.8	37
50	A longitudinal magnetic resonance spectroscopy study investigating effects of risperidone in the anterior cingulate cortex and hippocampus in schizophrenia. Schizophrenia Research, 2019, 210, 239-244.	1.1	37
51	An <scp>fMRI</scp> investigation of delay discounting in patients with schizophrenia. Brain and Behavior, 2013, 3, 384-401.	1.0	35
52	Contribution of substantia nigra glutamate to prediction error signals in schizophrenia: a combined magnetic resonance spectroscopy/functional imaging study. NPJ Schizophrenia, 2015, 1, 14001.	2.0	35
53	A Longitudinal Multimodal Neuroimaging Study to Examine Relationships Between Resting State Glutamate and Task Related BOLD Response in Schizophrenia. Frontiers in Psychiatry, 2018, 9, 632.	1.3	34
54	Examining resting-state functional connectivity in first-episode schizophrenia with 7T fMRI and MEG. Neurolmage: Clinical, 2019, 24, 101959.	1.4	34

#	Article	IF	Citations
55	Antipsychotic Drugs Alter Functional Connectivity between the Medial Frontal Cortex, Hippocampus, and Nucleus Accumbens as Measured by H215O PET. Frontiers in Psychiatry, 2012, 3, 105.	1.3	33
56	Race and Medication Adherence Moderate Cessation Outcomes in Criminal Justice Smokers. American Journal of Preventive Medicine, 2015, 49, 335-344.	1.6	33
57	Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication. Psychiatry Research - Neuroimaging, 2014, 221, 6-12.	0.9	32
58	Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers. Neuropsychopharmacology, 2020, 45, 1842-1850.	2.8	32
59	Digital Trajectories to Care in First-Episode Psychosis. Psychiatric Services, 2018, 69, 1259-1263.	1.1	31
60	Evaluation of fronto-striatal networks during cognitive control in unmedicated patients with schizophrenia and the effect of antipsychotic medication. NPJ Schizophrenia, 2018, 4, 8.	2.0	31
61	NMDA-Sensitive Glutamate Antagonism A Human Model for Psychosis. Neuropsychopharmacology, 1999, 21, S158-S169.	2.8	30
62	White matter integrity, duration of untreated psychosis, and antipsychotic treatment response in medication-naÃ-ve first-episode psychosis patients. Molecular Psychiatry, 2021, 26, 5347-5356.	4.1	29
63	Absence of ketamine effects on memory and other cognitive functions in schizophrenic patients. Journal of Psychiatric Research, 1996, 30, 321-330.	1.5	28
64	Mitochondria in the striatum of subjects with schizophrenia: Relationship to treatment response. Synapse, 2011, 65, 215-224.	0.6	27
65	Magnetic Transfer Contrast Accurately Localizes Substantia Nigra Confirmed by Histology. Biological Psychiatry, 2013, 73, 289-294.	0.7	27
66	Relationship Between Cortical Excitation and Inhibition and Task-Induced Activation and Deactivation: A Combined Magnetic Resonance Spectroscopy and Functional Magnetic Resonance Imaging Study at 7T in First-Episode Psychosis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 121-130.	1.1	27
67	Association Between Eye Tracking Disorder in Schizophrenia and Poor Sensory Integration. American Journal of Psychiatry, 1998, 155, 1352-1357.	4.0	25
68	Mnemonic Discrimination Deficits in First-Episode Psychosis and a Ketamine Model Suggests Dentate Gyrus Pathology Linked to N-Methyl-D-Aspartate Receptor Hypofunction. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 231-238.	1.1	25
69	Fourâ€way multimodal fusion of 7Â <scp>T</scp> imaging data using an m <scp>CCA</scp> +j <scp>ICA</scp> model in firstâ€episode schizophrenia. Human Brain Mapping, 2018, 39, 1475-1488.	1.9	24
70	White matter and neurite morphology differ in psychogenic nonepileptic seizures. Annals of Clinical and Translational Neurology, 2020, 7, 1973-1984.	1.7	22
71	A Prospective Longitudinal Investigation of Cortical Thickness and Gyrification in Schizophrenia. Canadian Journal of Psychiatry, 2020, 65, 381-391.	0.9	22
72	Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia. Schizophrenia Research, 2013, 147, 348-354.	1.1	21

#	Article	IF	CITATIONS
73	Cognitive control network dysconnectivity and response to antipsychotic treatment in schizophrenia. Schizophrenia Research, 2019, 204, 262-270.	1.1	21
74	A pilot study of combined endurance and resistance exercise rehabilitation for verbal memory and functional connectivity improvement in epilepsy. Epilepsy and Behavior, 2019, 96, 44-56.	0.9	21
75	Ultrastructural evidence for glutamatergic dysregulation in schizophrenia. Schizophrenia Research, 2022, 249, 4-15.	1.1	21
76	Glutamate/glutamine concentrations in the dorsal anterior cingulate vary with Post-Traumatic Stress Disorder symptoms. Journal of Psychiatric Research, 2017, 91, 169-176.	1.5	20
77	Open label smoking cessation with varenicline is associated with decreased glutamate levels and functional changes in anterior cingulate cortex: preliminary findings. Frontiers in Pharmacology, 2014, 5, 158.	1.6	19
78	Biochemistry of the cingulate cortex in autism: An MR spectroscopy study. Autism Research, 2016, 9, 643-657.	2.1	19
79	Gyrification Connectomes in Unmedicated Patients With Schizophrenia and Following a Short Course of Antipsychotic Drug Treatment. Frontiers in Psychiatry, 2018, 9, 699.	1.3	19
80	Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-NaÃ-ve Patients With First-Episode Psychosis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 231-238.	1.1	19
81	A multimodal magnetoencephalography 7 T fMRI and 7 T proton MR spectroscopy study in first episode psychosis. NPJ Schizophrenia, 2020, 6, 23.	2.0	18
82	Ketamine induced changes in regional cerebral blood flow, interregional connectivity patterns, and glutamate metabolism. Journal of Psychiatric Research, 2019, 117, 108-115.	1.5	17
83	Micro- and Macrostructural White Matter Integrity in Never-Treated and Currently Unmedicated Patients With Schizophrenia and Effects of Short-Term Antipsychotic Treatment. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 462-471.	1.1	15
84	Aberrant static and dynamic functional patterns of frontoparietal control network in antipsychoticâ€naà ve firstâ€episode psychosis subjects. Human Brain Mapping, 2020, 41, 2999-3008.	1.9	15
85	Is there Evidence for Neurotoxicity in the Prodromal and Early Stages of Schizophrenia?. Neuropsychopharmacology, 2011, 36, 1779-1780.	2.8	14
86	Salience network glutamate and brain connectivity in medication-naÃ⁻ve first episode patients – A multimodal magnetic resonance spectroscopy and resting state functional connectivity MRI study. Neurolmage: Clinical, 2021, 32, 102845.	1.4	14
87	Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients. Translational Psychiatry, 2020, 10, 15.	2.4	13
88	Expectancies for the Effectiveness of Different Tobacco Interventions Account for Racial and Gender Differences in Motivation to Quit and Abstinence Self-Efficacy. Nicotine and Tobacco Research, 2014, 16, 1174-1182.	1.4	12
89	Vergence eye movements in patients with schizophrenia. Vision Research, 2014, 102, 64-70.	0.7	12
90	Neurometabolic abnormalities in the associative striatum in antipsychotic-na $\tilde{A}$ -ve first episode psychosis patients. Psychiatry Research - Neuroimaging, 2018, 281, 101-106.	0.9	12

#	Article	IF	CITATIONS
91	Hippocampal Dysconnectivity and Altered Glutamatergic Modulation of the Default Mode Network: A Combined Resting-State Connectivity and Magnetic Resonance Spectroscopy Study in Schizophrenia. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2022, 7, 108-118.	1.1	10
92	Neuroimaging as a Window Into the Pathophysiological Mechanisms of Schizophrenia. Frontiers in Psychiatry, 2021, 12, 613764.	1.3	10
93	A multimodal neuroimaging study investigating resting-state connectivity, glutamate and GABA at 7 T in first-episode psychosis. Journal of Psychiatry and Neuroscience, 2021, 46, E702-E710.	1.4	10
94	Ocular Convergence Deficits in Schizophrenia. Frontiers in Psychiatry, 2012, 3, 86.	1.3	9
95	Recent developments in the neuropharmacology of schizophrenia. American Journal of Health-System Pharmacy, 1995, 52, S5-S8.	0.5	8
96	The relationship between smooth pursuit eye movements and tardive dyskinesia in schizophrenia. Schizophrenia Research, 1998, 31, 141-150.	1.1	8
97	Subtle effects of ketamine on memory when administered following stimulus presentation. Psychopharmacology, 2005, 180, 385-390.	1.5	8
98	Schizophrenia, VIII: Pharmacologic Models. American Journal of Psychiatry, 2003, 160, 2091-2091.	4.0	7
99	Aberrant visual circuitry associated with normal spatial match-to-sample accuracy in schizophrenia. Psychiatry Research - Neuroimaging, 2011, 193, 138-143.	0.9	7
100	Predictors of medication adherence and smoking cessation among smokers under community corrections supervision. Addictive Behaviors, 2017, 65, 111-117.	1.7	7
101	Structural and Functional Default Mode Network Connectivity and Antipsychotic Treatment Response in Medication-NaÃ-ve First Episode Psychosis Patients. Schizophrenia Bulletin Open, 2021, 2, sgab032.	0.9	7
102	Neurite Orientation Dispersion and Density Imaging (NODDI) and duration of untreated psychosis in antipsychotic medication-naÃve first episode psychosis patients. NeuroImage Reports, 2021, 1, 100005.	0.5	7
103	Reinforcement learning abnormalities in the attenuated psychosis syndrome and first episode psychosis. European Neuropsychopharmacology, 2021, 47, 11-19.	0.3	7
104	Parametric study of accuracy and response time in schizophrenic persons making visual or auditory discriminations. Psychiatry Research, 2004, 127, 207-216.	1.7	6
105	Clinical Utility of Wearable Sensors and Patient-Reported Surveys in Patients With Schizophrenia: Noninterventional, Observational Study. JMIR Mental Health, 2021, 8, e26234.	1.7	6
106	D2-Family Receptors in Schizophrenia: Distribution and Implications for Treatment. Clinical Neuropharmacology, 1995, 18, S110-S120.	0.2	5
107	Making Progress Toward Individualized Medicine in the Treatment of Psychosis. American Journal of Psychiatry, 2016, 173, 5-7.	4.0	5
108	The effect of saccadic eye movements on the sensor-level magnetoencephalogram. Clinical Neurophysiology, 2017, 128, 397-407.	0.7	5

#	Article	IF	CITATIONS
109	Baseline Functional Connectivity Predicts Connectivity Changes Due to a Small Dose of Midazolam in Older Adults. Anesthesia and Analgesia, 2020, 130, 224-232.	1.1	5
110	Neural Signatures of Memory Encoding in Schizophrenia Are Modulated by Antipsychotic Treatment. Neuropsychobiology, 2021, 80, 12-24.	0.9	5
111	The neural substrates of neurological soft signs in schizophrenia: a systematic review. NPJ Schizophrenia, 2022, 8, .	2.0	4
112	Clinical Genetics, V: Association of Genetic and Personality Characteristics. American Journal of Psychiatry, 1997, 154, 1496-1496.	4.0	3
113	White Matter Neurometabolic Signatures Support the Deficit and Nondeficit Distinction in Antipsychotic-NaÃ-ve First-Episode Psychosis Patients. Schizophrenia Bulletin, 2021, 47, 1068-1076.	2.3	3
114	Regional correlations between ketamine-induced actions on psychosis and regional cerebral blood flow (rCBF). Schizophrenia Research, 1997, 24, 167-168.	1.1	2
115	The Problem of Spurious Correlations Between Pairs of Brain Metabolite Values Measured in the Same Voxel With Magnetic Resonance Spectroscopy—Reply. JAMA Psychiatry, 2014, 71, 339.	6.0	2
116	325. Clinical Utility Study Towards the Use of Continuous Wearable Sensors and Patient Reported Surveys for Relapse Prediction in Patients at High Risk of Relapse in Schizophrenia. Biological Psychiatry, 2017, 81, S133.	0.7	2
117	Paving the Way for Targeted Drug Development in Schizophrenia. JAMA Psychiatry, 2018, 75, 19.	6.0	2
118	Rapid Clozapine Titration in an Acutely Agitated Patient With Schizoaffective Disorder. Journal of Clinical Psychopharmacology, 2016, 36, 276-277.	0.7	1
119	Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia. , 0, .		1
120	Mnemonic Discrimination Deficits in First-Episode Psychosis and a Ketamine Model Suggest Dentate Gyrus Pathology Linked to NMDA Receptor Hypofunction. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 1185-1192.	1.1	1
121	In vivo Experience With NRT to Increase Adherence and Smoking Abstinence Among Individuals in the Criminal Legal System: Study Protocol for a Randomized Clinical Trial. Frontiers in Psychiatry, 0, $13$ , .	1.3	1
122	GABA hypothesis of tardive dyskinesia: clinical neurochemistry and neurophysiology. Schizophrenia Research, 1989, 2, 237.	1.1	0
123	GABA hypothesis of tardive dyskinesia: pharmacology. Schizophrenia Research, 1989, 2, 239.	1.1	0
124	Combining 1 h MR spectroscopy and fmri during a prediction error task to evaluate the biochemical and functional properties of the sn/vta in individuals with schizophrenia and normal volunteers. International Clinical Psychopharmacology, 2011, 26, e129.	0.9	0
125	Cognitive risk profiles for anxiety disorders in a high-risk population. Psychiatry Research, 2015, 229, 572-576.	1.7	0
126	631. Brain Structure, Function, and Neurochemistry across Schizophrenia and Bipolar Disorder – A Systematic Review of the Magnetic Resonance Neuroimaging Literature. Biological Psychiatry, 2017, 81, S255-S256.	0.7	0

## ADRIENNE C LAHTI

#	Article	IF	CITATIONS
127	234. Hippocampal Glutamate and Resting State Functional Connectivity as Biomarkers of Treatment Response to Antipsychotic Medication. Biological Psychiatry, 2019, 85, S97.	0.7	O
128	117. Biomarker Assessment of Dose Dependent Target Engagement of mGluR-2,3 Partial Agonist for Schizophrenia Treatment. Biological Psychiatry, 2019, 85, S49.	0.7	0